As noted before, METTL3-m6A-EGFR-axis was responsible for acquired resistant to lenvatinib, and the particular METTL3 inhibitor STM2457 amplified tumor response to lenvatinib in HCC animal models via increasing cell apoptosis 40. This evidence concerns the gene EGFR and hepatocellular carcinoma.